Showing 121 - 140 results of 151,250 for search '(( 5 non decrease ) OR ( 10 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.11s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127

    Image_1_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif by Wan Fu (3681799)

    Published 2021
    “…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”
  8. 128

    Image_4_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif by Wan Fu (3681799)

    Published 2021
    “…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”
  9. 129

    Image_3_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif by Wan Fu (3681799)

    Published 2021
    “…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”
  10. 130

    Image_2_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif by Wan Fu (3681799)

    Published 2021
    “…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”
  11. 131

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  12. 132

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”
  13. 133
  14. 134
  15. 135
  16. 136
  17. 137
  18. 138
  19. 139

    Table_1_Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.docx by Ha Young Jang (1522204)

    Published 2022
    “…</p>Result<p>We followed-up (median: 5.6 years) 188,906 matched patients (94,453 LTRA users and 94,453 non-users). …”
  20. 140

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”